Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-rituximab consolidation in CD20-positive advanced diffuse large B-cell lymphoma after chemotherapy
KCT0000526Phase 2Recruiting
- Sponsor
- Korea Institute of Radiological & Medical Sciences
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Korea Institute of Radiological & Medical Sciences. Started May 2006; status: recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0000526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000526.